Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
Best Momentum Stock to Buy for July 7th
11:00am, Monday, 07'th Jul 2025
VRNA and EVLV made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 7, 2025.
New Strong Buy Stocks for July 7th
07:26am, Monday, 07'th Jul 2025
PRM, VRNA, SVNDY, TD and MSBHF have been added to the Zacks Rank #1 (Strong Buy) List on July 7, 2025.
Wall Street Analysts Predict a 25.99% Upside in Verona Pharma (VRNA): Here's What You Should Know
10:56am, Wednesday, 02'nd Jul 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the po
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
10:30am, Wednesday, 02'nd Jul 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
Here's Why Momentum in Verona Pharma (VRNA) Should Keep going
09:50am, Tuesday, 01'st Jul 2025
Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through
Verona Pharma: A Blockbuster Franchise In The Making
01:17am, Tuesday, 10'th Jun 2025
Ohtuvayre's rapid US launch has driven explosive revenue growth, with Q1 2025 sales up 95% sequentially and refill rates signaling strong patient demand. With blockbuster potential, Wall Street projec
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today
11:22am, Thursday, 05'th Jun 2025
If you want to achieve significant gains in the stock market, you'll probably want to plan to hold on and remain invested for many years, or even decades. But in some cases, big payoffs can come much
Mizuho's Jared Holz details potential biotech, pharma acquisitions
06:10pm, Wednesday, 04'th Jun 2025
Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and pharmaceuticals industries.
Verona Pharma Announces June 2025 Investor Conference Participation
06:00am, Wednesday, 21'st May 2025
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside cha
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
06:00am, Tuesday, 06'th May 2025
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population
Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster
08:51am, Thursday, 01'st May 2025
VRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a pha
Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript
03:45pm, Tuesday, 29'th Apr 2025
Verona Pharma plc (NASDAQ:VRNA ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Victoria Stewart - Senior Director, Investor Relations and Communications David Zaccard
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
06:00am, Tuesday, 29'th Apr 2025
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024)
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical
10:47am, Monday, 07'th Apr 2025
Ohtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is so
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS
07:00am, Friday, 28'th Mar 2025
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE)
